Evidence map›Paper›PMID 36841839›Full record

ArticleScientific reports2023

Differential expression of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) in Alzheimer's disease and HIV-1 associated neurocognitive disorders.

Armando Garces, Bryan Martinez, Roberto De La Garza, Deepa Roy, Kaylie-Anna Vallee, Jerel Adam Fields, David J Moore, Hansapani Rodrigo, Upal Roy

Abstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Burn Selection: How Fire Injury Shaped Human Evolution.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Armando GarcesDepartment of Health and Biomedical Sciences, University of Texas Rio Grande Valley, One West University Blvd, Brownsville, TX, 78520, USA.
Bryan MartinezDepartment of Health and Biomedical Sciences, University of Texas Rio Grande Valley, One West University Blvd, Brownsville, TX, 78520, USA.
Roberto De La GarzaDepartment of Health and Biomedical Sciences, University of Texas Rio Grande Valley, One West University Blvd, Brownsville, TX, 78520, USA.
Deepa RoyDepartment of Health and Biomedical Sciences, University of Texas Rio Grande Valley, One West University Blvd, Brownsville, TX, 78520, USA.
Kaylie-Anna ValleeDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Jerel Adam FieldsDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
David J MooreDepartment of Psychiatry, University of California, San Diego, La Jolla, CA, USA.
Hansapani RodrigoSchool of Mathematical and Statistical Sciences, University of Texas Rio Grande Valley (UTRGV), Edinburg, TX, USA. hansapani.rodrigo@utrgv.edu.
Upal RoyDepartment of Health and Biomedical Sciences, University of Texas Rio Grande Valley, One West University Blvd, Brownsville, TX, 78520, USA. upal.roy@utrgv.edu.

Funding

STRUCTURAL NEUROIMAGING COREP30MH062512 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jessica Lynette Montoya · 2001 to 2026
$50.4M
A targeted anti-HIV drug delivery to the GALTR01AI147731 · NIAID · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI ROY, UPAL · 2020 to 2025
$3.3M
The role of TFAM alterations in HIV- and ART-induced mitochondrial dysfunction in the brainR01MH128108 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jerel Adam Fields · 2022 to 2026
$2.3M
Nanodiamond based anti-HIV drug delivery targeted towards the brainR15NS108815 · NINDS · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI ROY, UPAL · 2018 to 2018
$433k
NIAID NIH HHS R01 AI147731NIH HHS R15NS108815,R01AI147731,NIMH NIH HHS P30 MH062512NIMH NIH HHS R01 MH128108NINDS NIH HHS R15 NS108815
6 · The paper itself

Abstract

The United Nations projects that one in every six people will be over the age of 65 by the year 2050. With a rapidly aging population, the risk of Alzheimer's disease (AD) becomes a major concern. AD is a multifactorial disease that involves neurodegeneration in the brain with mild dementia and deficits in memory and other cognitive domains. Additionally, it has been established that individuals with Human Immunodeficiency Virus-1 (HIV-1) experience a 5 to 10-year accelerated aging and an increased risk of developing HIV-associated neurocognitive disorders (HAND). Despite a significant amount of clinical evidence pointing towards a potential overlap between neuropathogenic processes in HAND and AD, the underlying epigenetic link between these two diseases is mostly unknown. This study is focused on identifying differentially expressed genes observed in both AD and HAND using linear regression models and a more robust significance analysis of microarray. The results established that the dysregulated type 1 and 2 interferon pathways observed in both AD and HAND contribute to the similar pathologies of these diseases within the brain. The current study identifies the important roles of interferon pathways in AD and HAND, a relationship that may be useful for earlier detection in the future.

Indexed as

AIDS Dementia ComplexAlzheimer DiseaseHIV-1HIV InfectionsAgedHumansInterferonsIntracellular Signaling Peptides and ProteinsNeurocognitive DisordersTetratricopeptide RepeatIFIT3 protein, humanInterferonsIntracellular Signaling Peptides and Proteins

Identifiers

PMID36841839
PMCPMC9968324

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.